Global Irritable Bowel Syndrome Treatment Market with present Situation and Forecast To 2026
The treatment of
irritable bowel syndrome majorly revolves around relieving the
patient from the symptoms associated with the condition, as the
causes behind occurrence of irritable bowel syndrome are yet to be
established. Patients suffering from irritable bowel syndrome show
symptoms such as abdominal pain, diarrhea, and constipation.
Long-term and recurring presence of these symptoms signals the
possibility of irritable bowel syndrome. The treatment depends on
severity of these symptoms, which are distinguished as mild,
moderate, and severe. Mild symptoms do not significantly affect the
quality of life. However, severe symptoms are more frequent and
intense and need to be addressed. The disease is often linked with
dietary, lifestyle factors, and stress, which can be controlled by
managing stress levels, diet, and exercise. Severe symptoms need to
be treated through medication prescribed by physicians. Two major
therapy options are available for the treatment of IBS, namely,
medical or drug therapy and nutritional therapy. Medical therapy
includes drugs for relieving the symptoms and nutritional therapy by
using fibers and probiotics or prebiotics depending on the situation.
Some major
players operating in the irritable bowel syndrome treatment market
are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo
Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc.,
Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline
plc., and Ironwood Pharmaceuticals, Inc.
Request Sample
Copy Of This Research Report:
Market Dynamics
The rise in number
of gastrointestinal disorders are leading to increasing prevalence of
irritable bowel syndrome, for which various companies such as
Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops
for educating the people to incorporate healthy food habits as a
major precaution towards prevention of IBS. Furthermore, major growth
drivers for the irritable bowel syndrome treatment market are
expected launches of various pipeline drugs for the treatment during
the forecast period and increase in levels of stress associated with
changing lifestyle as people suffering from IBS have a colon with
sensitivity towards certain foods and stress. According to a survey
by Buscopan IBS Relief in 2016, stress was the cause for seven out of
ten patients suffering from gastrointestinal pain. The large
population of stress and anxiety disorder patients are expected to
fuel the growth of the global irritable bowel syndrome treatment
market.
Market Taxonomy
This report segments
the global irritable bowel syndrome treatment market on the basis of
drug type, medical condition, and distribution channel. On the basis
of drug type, the global irritable bowel syndrome treatment market is
segmented into lubiprostone, linaclotide, eluxadoline, rifaximin,
Ramosetron Hydrochloride and others. Medical conditions of irritable
bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable
bowel syndrome treatment market is segmented by distribution channel
as hospital pharmacies, online pharmacies and retail pharmacies.
Key features of
the study:
This report provides
in-depth analysis of irritable bowel syndrome treatment market and
provides market size (US$ Million) and Cumulative Annual Growth Rate
(CAGR %) for the forecast period (2017–2025), considering 2017 as
the base year
It elucidates
potential revenue opportunity across different segments and explains
attractive investment proposition matrix for this market
This study also
provides key insights about market drivers, restraints,
opportunities, new product launches or approval, regional outlook,
and competitive strategy adopted by the leading players
It profiles leading
players in the global irritable bowel syndrome treatment market based
on the following parameters – company overview, financial
performance, product portfolio, geographical presence, distribution
strategies, key developments and strategies, and future plans
Key companies
covered as a part of this study include Abbott Laboratories*, Synergy
Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant
Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma
Inc., Novartis AG, GlaxoSmithKline plc., Ironwood Pharmaceuticals,
Inc.
Insights from this
report would allow marketers and the management authorities of the
companies to make informed decision regarding their future product
launch, technology up-gradation, market expansion, and marketing
tactics
The global irritable
bowel syndrome treatment market report caters to various stakeholders
in this industry including investors, suppliers, drug manufacturers,
distributors, new entrants, and financial analysts
Stakeholders would
have ease in decision making through the various strategy matrices
used in analyzing the Irritable Bowel Syndrome Treatment Market
Download the PDF
brochure:
Detailed
Segmentation:
Global Irritable
Bowel Syndrome Treatment Market, By Drug Type:
Lubiprostone
Linaclotide
Global Irritable
Bowel Syndrome Treatment Market, By Medical Condition:
IBS-Constipation
IBS-Diarrhea
Global Irritable
Bowel Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Global Irritable
Bowel Syndrome Treatment Market, By Geography:
North America
Europe
Asia-Pacific
Latin America
Middle East
Africa
About Coherent
Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market
Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Visit our news
Website: https://www.coherentwire.com
Comments
Post a Comment